As bioprocessing teams explore perfusion to increase productivity and extend culture duration, they need a development platform that makes evaluation simple, scalable, and data-rich.
Our latest Technical Bulletin demonstrates the expanded potential of high-density TFF perfusion on the Stratyx™ platform through a controlled side-by-side comparison with fed-batch. Using the same CHO cell line, inoculum, and operating conditions, TFF perfusion delivered compelling improvements across every major productivity metric.
Study Highlights
- 13× higher volumetric productivity
- 29× more total IgG produced
- 35-day culture duration while maintaining >90% viability
- 3.3× higher cell-specific productivity (Qp)
These results demonstrate how Stratyx can support the evaluation of high-density perfusion alongside traditional fed-batch workflows on a single automated platform, giving process development teams the flexibility to compare strategies while capturing comprehensive process data.
Download the Technical Bulletin to explore the complete study, methodology, and performance results.
